Saige-Density (2.5.0)

by DeepHealth  · Based in United States →AI-powered health informatics for radiology
Oncology Radiology

Contact for pricing
Regulatory Status Disclosed

Overview

Saige-Density (2.5.0) by DeepHealth is a Software as a Medical Device (SaMD) designed to automate the assessment of breast tissue composition. Developed for interpreting radiologists and breast imaging specialists, the tool assists in evaluating mammography exams within clinical and screening environments.

The software integrates directly into existing radiology workflows by processing DICOM files from compatible full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) systems. It operates in the background, analyzing 2D mammogram images (including synthetic 2D views) using deep learning algorithms. Rather than utilizing a standalone graphical user interface, Saige-Density outputs its findings directly to the PACS or mammography viewing workstation.

Notable capabilities include:

  • Automatic generation of a study-level breast density category aligned with the ACR BI-RADS Atlas 5th Edition (categories A through D).
  • Standardized output delivery via two DICOM objects: a Structured Report (SR) containing the case-level density category and a Secondary Capture (SC) summary report.
  • Compatibility with leading enterprise imaging viewers, enabling density scores to display directly within CAD headers or image overlays.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Automated breast density categorization (ACR BI-RADS classification)
  • Aids interpreting physicians in breast tissue assessment
  • Reduces subjectivity and variability in density assessments
  • Adjunctive AI software (not a diagnostic aid)
  • Compatible with FFDM and DBT systems
  • Trained on a diverse database of mammography images
  • Part of DeepHealth's Breast Suite for enhanced workflow
  • Integrates into existing breast cancer diagnostic workflows
  • Provides consistent, automated density classification
  • Outputs DICOM Structured Report (SR) and Secondary Capture (SC) objects

Use Cases

  • Assessing breast density during mammography exams
  • Supporting radiologists in accurate and consistent breast density determinations
  • Facilitating earlier identification of breast cancer through improved density assessment
  • Aiding compliance with national standards for breast density notification

What Physicians Need to Know

Key Capabilities
Saige-Density automatically assesses breast tissue composition using deep learning, generating ACR BI-RADS Atlas 5th Edition breast density categories (A, B, C, or D). It processes images from full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) systems, outputting DICOM structured reports and secondary capture objects with the density category.
Clinical Utility
This tool aids radiologists in achieving more accurate and consistent breast density determinations, thereby reducing subjectivity in visual analysis. It is particularly valuable for the earlier identification of cancer, especially in women with dense breast tissue where detection can be challenging. Saige-Density also helps healthcare providers meet state laws and upcoming FDA requirements for breast density notification. It is an adjunctive tool, not intended to replace a physician's diagnostic judgment.
Integration Options
Saige-Density is designed for use with compatible FFDM and DBT systems. It outputs standard DICOM files (SR and SC) that can be viewed on mammography workstations. DeepHealth, as a subsidiary of RadNet, suggests potential integration within RadNet's broader imaging network. Furthermore, an expanded collaboration with GE HealthCare enables distribution of Saige-Density within GE HealthCare's Breast Suite, which includes a cloud-first multi-modality viewer and PACS functionality.
Compliance Status
The software is FDA 510(k) cleared (K222275) as of December 16, 2022, and is classified as a Class II Medical Device and Software as a Medical Device (SaMD).
Pricing Model
Specific details regarding the pricing model for Saige-Density are not publicly available and typically require direct inquiry with DeepHealth or its partners.
User Experience
The tool is intended to assist interpreting physicians by providing objective and consistent breast density assessments. Integration with platforms like GE HealthCare's Breast Suite suggests a streamlined user experience within a unified diagnostic workspace, enhancing image management and interpretation.
Implementation Complexity
As a software application, Saige-Density integrates with existing FFDM and DBT systems and outputs standard DICOM files, which should facilitate integration into current PACS/RIS workflows. The GE HealthCare collaboration mentions deployment through 'low-cost infrastructure' for related platforms, suggesting a potentially manageable implementation.
Evidence Base
Saige-Density's performance was validated through a multi-site retrospective study. It demonstrated an 81.28% accuracy for four-class BI-RADS categorization compared to the consensus of five expert radiologists. Another study showed 91.5% alignment with expert consensus. The AI algorithm was trained on a diverse dataset of over 166,000 images from 30,000 mammography exams across the United States, with non-clinical and clinical testing confirming its safety and effectiveness.
Physician Tip

Saige-Density serves as a valuable adjunctive tool to enhance the objectivity and consistency of breast density assessment, which is crucial for patient risk stratification and adherence to regulatory guidelines. Remember that it is an aid and should always be used in conjunction with your comprehensive clinical judgment and review of the mammogram. Leverage its automated categorization to streamline reporting and ensure consistent communication with patients regarding their breast density.

Saige-Density's output in standard DICOM formats (SR and SC) is designed for straightforward integration into existing mammography viewing workstations and PACS/RIS environments. Its compatibility with both FFDM and DBT systems ensures broad applicability. For users within the RadNet ecosystem or those utilizing GE HealthCare's Breast Suite, deeper, more seamless integration and workflow enhancements are likely available.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentCloud-native (DeepHealth OS)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Saige-Density (2.5.0) received 510(k) clearance (K243705) from the FDA on December 19, 2024. It is an adjunctive AI software intended to aid interpreting physicians in the assessment of breast tissue composition by providing an ACR BI-RADS Atlas 5th Edition breast density category.

Integrations
EHR Not specified
Specialties Oncology, Radiology

What the Web Says

Saige-Density (2.5.0) is an FDA-cleared artificial intelligence software developed by DeepHealth, Inc. for automated radiological image processing and analysis in mammography and digital breast tomosynthesis (DBT). It functions by outputting DICOM files (structured and secondary capture reports) that are then viewed on a mammography viewing workstation or integrated with existing PACS systems, rather than having its own primary user interface for direct interaction or image review. The software is designed to assist physicians in detecting subtle lesions and improving the accuracy of mammogram interpretations, with studies indicating improved performance for both general radiologists and breast imaging specialists.

Overall: Positive

Strengths

  • FDA-cleared for mammography and DBT.
  • Improves breast cancer detection rates.
  • Enhances accuracy for both general radiologists and breast imaging specialists.
  • Identifies subtle lesions that are difficult to find manually.
  • Reduces false alarms and patient anxiety.
  • Delivers equitable results across diverse patient populations, including women with dense breasts and various racial/ethnic groups.

Limitations

  • Lacks its own direct user interface for image review, relying on integration with existing PACS or viewing workstations.
  • May lead to a slight increase in recall rates, though balanced by increased cancer detection.
  • Information on pricing is not readily available in the search results.
  • Specific physician reviews outside of study contexts are not widely published in the provided search results.
  • No reviews found on G2, Capterra, or Reddit.

Based on reviews from: Innolitics, Radiology AI Tools Directory, DeepHealth - Physician Ai Tools, FDA, BEUDAMED, Enhanced Breast Cancer Detection, Impact of a Categorical AI System for Digital Breast Tomosynthesis on Breast Cancer Interpretation by Both General Radiologists and Breast Imaging Specialists - PMC, Diagnostic Imaging, Landmark Nature Health Study Demonstrates the Effectiveness of DeepHealth's Novel AI-Powered Breast Cancer Detection Workflow

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Saige-Density (2.5.0)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Videos

Product demos, reviews, and walkthroughs for Saige-Density (2.5.0).

Loading videos...

View all on YouTube

Frequently Asked Questions

Saige-Density (2.5.0) is an AI-based software that processes screening and diagnostic digital mammograms to automatically generate an American College of Radiology (ACR) BI-RADS breast density category. This tool is designed to aid interpreting radiologists in making consistent and accurate breast density determinations, reducing subjectivity in visual analysis.
Saige-Density (2.5.0) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), classifying it as Software as a Medical Device (SaMD). This clearance indicates that the device is substantially equivalent to a predicate device and is intended for use with compatible full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) systems.
Saige-Density (2.5.0) is an adjunctive tool and is not intended to replace a physician's own review of a mammogram or their clinical judgment. Decisions regarding patient care should not be made solely based on the analysis provided by Saige-Density.
The software takes a single x-ray mammogram study as input, processing all acceptable 2D image DICOM files (FFDM and/or 2D synthetics) to generate a study-level breast density category. It outputs two DICOM files, including a structured report, which can be integrated into existing viewing workstations.
While manual visual assessment by radiologists is a traditional method, Saige-Density (2.5.0) offers an AI-powered alternative designed to improve accuracy and consistency in assigning ACR BI-RADS breast density categories. It aims to reduce the subjectivity inherent in visual analysis, complementing the radiologist's expertise.
In a retrospective, multicenter study, Saige-Density showed a 91.5% alignment with consensus breast density assessments by five breast imaging specialists. Its accuracy on four-class categorization (density categories A, B, C, or D) was reported as 81.28% (95% CI: 78.42, 83.84).
Specific pricing details for Saige-Density (2.5.0) are not publicly disclosed in the provided search results. However, it is developed by DeepHealth, a subsidiary of RadNet, which offers AI-powered solutions for breast cancer detection and workflow enhancement.

Related Tools

FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
eyonis® LCS
Median Technologies
Oncology AI
eyonis® LCS is an FDA 510(k) cleared AI/machine learning-powered software for the detection and diagnosis of lung cancer, helping clinicians detect and characterize suspicious parenchymal pulmonary nodules earlier on low-dose CT scans.
Lumea Digital Pathology
Lumea
Clinical Decision Support & Reference
Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow, from biopsy to final report, and integrates AI tools from partners like Paige and Mindpeak.
Azra AI
Azra AI
Clinical Decision Support & Reference
Azra AI is an AI platform that swiftly analyzes, identifies, and classifies cancer patients, triaging those needing therapy and follow-up to enhance oncology care. It is deployed at more than 1,500 sites and integrated with leading EHRs.
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.

See all Oncology AI tools →

More from DeepHealth

Saige-Density
DeepHealth
Oncology AI
AI-powered software for automated breast density assessment in mammography, aiding radiologists in consistent BI-RADS classification and reducing subjectivity.
Saige-Dx
DeepHealth
Oncology AI
AI-powered mammography diagnostic software that assists radiologists in detecting breast cancer earlier and more accurately by identifying suspicious lesions and assigning suspicion levels in mammograms.
Saige-Q
DeepHealth
Oncology AI
Saige-Q is an FDA-cleared AI software by DeepHealth that processes mammograms to prioritize suspicious cases for radiologists, enhancing workflow efficiency and supporting early breast cancer detection.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18

Investors who backed Saige-Density (2.5.0)

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.